Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

Jeff Coller and Michelle Kim explain the origin of the Center and how getting low-cost RNA based molecules into the hands of academics drives innovation.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Established in 1997, Ergomed is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support ...

Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate resources effectively. In 2025, staying ahead of these changes will be vital ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...